Subject line
-
-
We question subject line option 1, as "See why you should prescribe.." is absolute and unsubstantiated, and inclusion of the product and therapeutic use prompts the requirement for the indication and fair balance. As the email envelope has limited space, please revise to reflect a neutral message. We note that the layout does not match the copydeck for all subject lines, please note the copydeck has been reviewed. Please refer to tips for email envelopes on the PAAB website. (s2.6, s3.1)
-
The combination of the product and study name "study Y' as inclusion of both elements is not acceptable in the context of a subject line, as it prompts the need for indication/fair balance. Please revise to include only one element. If the study name is included, please provide support and clarify if this is the name of the pivotal study in the product monograph. We note the study name has not been specified in the copydeck and LUNGBREAK is not supported by the PM. Further comments may arise pending receipt of response. (s3.1)
-
Similar to point 2, inclusion of the study the product name and study are not acceptable in the context of a subject line, please select one element and revise to reflect a neutral claim (i.e. revise study results to study data).
-